Oska® Wellness Honored with MedTech Breakthrough Award

CARLSBAD, CA, June 7, 2017 – Oska Wellness, a technology company committed to developing consumer health and wellness products, announced that its Oska Pulse has been selected as the “Best IoT Healthcare Wearable Device” award winner from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies and products in the global health and medical technology market.

“All of us at Oska are excited to receive this award from MedTech, who have recognized Oska’s mission to provide non-invasive, drug-free pain management solutions,” said Greg Houlgate, Oska Wellness CEO. “This is an important industry recognition for our year-old company and our flagship device, Oska Pulse. We’re very grateful.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Patient Engagement, Electronic Health Records (HER), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 2,000 nominations from more than 10 countries. All nominations were evaluated by an independent panel of experts within the medical and health industry, including media, analysts, and technology executives.

“We are thrilled to recognize Oska Wellness with this well-deserved industry recognition for innovation in the health and medical technology field,” said James Johnson, managing director, MedTech Breakthrough. “For the millions of Americans that suffer from chronic pain, Oska Pulse is a compelling solution and the MedTech Breakthrough Award designation is a testament to the skill, ingenuity, and vision of the Oska Wellness team.”

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

About Oska Wellness 
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

About MedTech Breakthrough
The MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough MedTech companies and products in categories including Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Genomics, Medical Data, Healthcare Cybersecurity and more. For more information visit www.MedTechBreakthrough.com

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

 

 

 

 

Life Spine® Achieves Record Breaking Sales Growth of Biologics Product Line over Past Year

June 06, 2017

HUNTLEY, Ill.–(BUSINESS WIRE)–Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today exponential growth of their Biologics product line, OSTEO-LINK™ Demineralized Bone Matrix, over the past fiscal year.

“OSTEO-LINK has been engineered and processed to deliver the highest level of osteoinductivity. It is because of this technology that we have achieved record breaking revenue growth of 424% over the past year,” said Mariusz Knap, Vice President of Marketing for Life Spine. “From April to May alone, we experienced a 270% revenue jump. This has been possible through our many differentiated offerings of putty, strips, cubes and fillers all available to help influence better patient outcomes and reduce costs.”

Life Spine expects continued growth of their Biologics line with the announcement of two new Biologic offerings. First, OSTEO-LINK Hydratable ICM (Inductive Carrier Matrix), which is an osteoinductive bone matrix that may be hydrated with saline, blood, BMA, or PRP. OSTEO-LINK Hydratable ICM does not contain any extrinsic carriers and is made from 100% human bone. The graft also has exceptional handling characteristics that resists irrigation. All OSTEO-LINK products are verified for osteoinductivity post-sterilization prior to release for distribution. In-vivo test results demonstrate all 5 bone forming elements present (chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone).

Second, the patent pending MARROW CELLUTION™ Bone Marrow Harvesting System, designed to overcome the limitations of a traditional bone marrow needle and results in a bone marrow harvest that is so rich in key stem and progenitor cells that the aspirate may no longer require manipulation through centrifugation prior to application. Traditional needles produce excess peripheral blood contamination, diminishing cellular yield; thereby requiring additional manipulation steps to achieve the cellular demand necessary for most clinical indications. MARROW CELLUTION uses its patent(s) pending technology to harvest high quality stem and progenitor cells from various levels within the marrow space, while limiting peripheral blood contamination.

About Life Spine

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com.

Contacts

Life Spine
Mr. Omar Faruqi
Chief Financial Officer
ofaruqi@lifespine.com
847-884-6117

Oska® Wellness Teams Up With Arizona Golf Association to Promote the Revolutionary Oska Pulse

CARLSBAD, Calif., May 31, 2017 /PRNewswire/ — Oska Wellness, a technology company committed to developing innovative consumer health and wellness products, is partnering with the Arizona Golf Association to promote Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain.  The AGA is comprised of more than 400 clubs and 75,000 members.

“I used Oska Pulse both prior to and after my hip surgery last year,” said Ed Gowan, Executive Director of the AGA.  “We’re always interested in bringing new products and options to Arizona Golf members. If they can use Oska Pulse to play one more round, then we’re all for recommending it to our community.”

Oska Pulse is a safe, easy-to-use, wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

“I met Ed Gowan in 2010 while in the golf industry and am delighted to forge an official relationship with the Arizona Golf Association,” said Steve Collins, COO of Oska Wellness. “The AGA shares our mission for new ways to provide non-invasive, drug-free pain management solutions. Many golfers have told us that they’ve had to cut back on playing due to elbow, hip, wrist, knee, back pain and more. Those who have used Oska Pulse now view the device as just as important to managing their aches and pains as a putter or a driver is to his or her game.”

The Arizona Golf Association was founded in 1923 as a small group of golfers who got together to run the annual Amateur Championship.  The AGA is a volunteer-based organization directed by amateur golfers, dedicated to promoting the game of golf, and providing valuable benefits and services to its members.

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives.  Subsequently, Oska Pulse was named “best in show” by top golf publications, including Golf Digest.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

CONTACT:
Robin Carr, Oska, Inc.
415-971-3991
162247@email4pr.com

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oska-wellness-teams-up-with-arizona-golf-association-to-promote-the-revolutionary-oska-pulse-300465961.html

Kuros Biosciences submits MagnetOs Putty for US FDA Clearance

06 Jun 17

Kuros (SIX:KURN) today announced it has filed the submission package for MagnetOs Putty seeking 510(k) clearance from the US Food and Drug Administration (FDA) for use as an autograft extender in posterolateral spine. MagnetOs is a novel synthetic bone graft substitute designed to support bone healing in the implanted site in the body. MagnetOs Putty is a moldable putty formulation of MagnetOs Granules, which is already cleared for commercialization in the United States of America and the European Union.

Dr. Ivan Cohen-Tanugi, Chief Executive Officer of Kuros, commented: “This FDA filing is yet another important milestone for Kuros as it eventually expands our portfolio of commercial-stage products. A similar submission for MagnetOs Putty in the EU will be filed in the next months.” He continued: “MagnetOs features a unique surface science technology that supports local bone formation. To meet surgeons’ preferences, we are developing a comprehensive product line consisting of different formulations and applications of MagnetOs. Furthermore, we plan to extend the existing labels into additional indications.”

MagnetOs Putty advantage

According to Kuros estimates, there are over 3 million procedures worldwide each year that use a bone graft material or a substitute. Patient-own bone (autograft) is still considered the gold standard bone grafting material. However, harvesting healthy bone usually requires a separate surgical procedure with associated costs, risks and morbidity.  Therefore, an extender that can be used in combination with local autograft, without the need for a separate autograft harvest procedure, offers significant potential benefits. Animal testing demonstrates comparable rates of bone healing for MagnetOs when used as an extender with autograft compared to autograft alone in a rabbit posterolateral fusion model.

Oska® Pulse is a “Best Product” Award Winner at ING Conference

CARLSBAD, CA, June 1, 2017 – Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain, was recently named “Best Product” at the 27th Annual ING Spring Conference. Oska Pulse, the flagship product from Oska Wellness, received the award last month at the World Golf Village & Hall of Fame in St. Augustine, FL.

The ING Spring Conference is an annual gathering of media and golf industry executives conducted by the non-profit networking organization, the International Network of Golf. A group of 130 industry executive and media were in attendance at this years’ event, held May 21- 24.  The Oska Pulse and the Knuth Golf High Heat fairway metals tied in voting by attendees who chose their favorite products which were demoed at the conference.

“We are thrilled to be honored by the folks who attended the ING Conference and who recognize Oska’s mission to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “It was an inspirational week at the conference, and we heard from golfers who deal with elbow, hip, wrist, knee, back pain and more. With Oska Pulse, golfers can play another round — pain free.”

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives. Oska Pulse was named “best in show” by top golf media outlets who attended, including Golf Digest, Golf Channel, and TravelingGolfer.net.

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

 

 

Accelerant Venture Capital Fund Approves Investment in AMB Surgical

June 1, 2017

DAYTON, Ohio – The Accelerant Venture Capital Fund recently approved investment in AMB Surgical to support the company’s development of a prototype for its Flyte Automated Growing Rod, a medical device that could revolutionize the way physicians treat juvenile scoliosis, lengthen limbs, and stabilize traumatic injuries.

The company founders bring decades of engineering experience to their work, as well as a personal mission to make such surgeries less traumatic for young patients.

Founder Casel Burnett would know. His daughter was diagnosed with juvenile scoliosis as a young child and endured years of invasive surgeries as part of the treatment. Scoliosis, or curvature of the spine, can lead to life-long health issues if not corrected while the child is still growing. Watching his daughter undergo treatment motivated him to find a better way.

“AMB embodies the innovative spirit and hard work that characterize the Dayton Region,” said Roger Edwards, Vice President of Accelerant Venture Capital Fund, an initiative of the Dayton Development Coalition. “Their work has the potential to revolutionize the way these conditions are treated and spare young patients repeated, invasive procedures.”

Burnett is a mechanical engineer and group manager of production engineering at Toyota, and partnered with friend Tyson Ross, an electrical controls engineer and program manager at the U.S. Air Force Research Laboratory, to see how they could take the existing technology and improve it. Ross and Burnett are confident they have found the answer.

AMB uses patented technology to electronically control the extension of rods used in orthopedic surgeries. Current devices use manual adjustments, either by having caretakers, such as parents, use tools to adjust an external framework for limb extension, or, for scoliosis, through repeated back surgeries. A physician implants an adjustable rod along the child’s spine, and as the child grows, uses tools to lengthen the rod through additional surgeries to correct the curve.

Flyte would allow the physician to expand the rod remotely, without surgery, as the child grows, both cutting down on the number of surgeries and potentially accelerating the treatment. It would eliminate the need for parents to adjust external frames, as well as reduce the likelihood of missing adjustments.

The key to their technology is tiny gear box located in the rod that has a microchip and RFID reader to program adjustments and record information.

Dr. Michael Albert, Director or Orthopaedics at Dayton Children’s Hospital, called the product a “game changer” in this type of treatment.

“We have made significant progress in the safety and design of limb lengthening external fixator devices, but what has been lacking is an automated, safe and reliable device that removes the patient or family from making daily adjustments,” Dr. Albert wrote in a letter of support for AMB.

Ross said they plan to develop a prototype with the current round of funding, starting with a rod that would be used in external frames, then moving on to implanted rods for scoliosis treatment and other internal uses.

For physicians, the device would also provide valuable feedback they can’t access today. The same technology that allows the device to adjust, allows it to collect data on the patient’s progress. The company already holds patents on the technology, and the initial research and design have generated interest from world leaders in pediatric orthopedic surgery.

“How small can we go? That’s the real question,” Ross said. “There’s tremendous potential for this type of technology, and we are confident we can bring it to market.”

The product would need to undergo testing and approval from the Federal Drug Administration.

The investment marks the 10th investment for Accelerant, the region’s only institutional VC fund with resources ready to invest in local companies. AMB has attracted significant “sidecar” investment as well, as private local investors find increasing opportunities to invest in start-ups in the Dayton Region.

“In the last year, we’ve seen a real shift in funding for local start-ups,” Edwards said. “The support and investment of local ‘angel investors’ is vital for start-ups to flourish. It’s exciting to connect local entrepreneurs to investors in the Dayton Region so they can grow their businesses here.”

AMB’s technology has generated interest from outside the Dayton region, as well. Dan Sands, a 25-year healthcare industry executive, has identified and is retaining world-renowned surgeon advisors, subject matter experts in engineering, accredited investment sources, and potential strategic commercialization entities.

“The positive market interest for this technology has been extraordinary,” said Sands, CEO of D11, LLC, who has spent most of his career in Warsaw, Ind., a city known within the industry as the “Orthopaedic Capital.” “Flyte’s ability to give surgeons real-time biomechanical stress/strain data will allow more accurate and timely remote non-surgical adjustments. This represents a game changing advancement in orthopaedics and could lead to a new frontier in bionic implantable devices that improves the total cost and quality of care.”

AMB plans to engage The Ohio State University’s Center for Design and Manufacturing Excellence and other expert resources as part of its efforts to develop the initial productionready prototypes. The Ohio State center plans to leverage its expertise to facilitate design feasibility, component and systems development, prototyping, manufacturing scale, and workforce development. “Working with Ohio State’s CDME brings resources and expertise to the process at an early stage that is difficult to find elsewhere in the country,” Ross said.

As for the young girl who inspired this technology, Burnett’s daughter Ashley Mae is all grown up, working as a nurse, and in great health. She’s the name behind AMB.

“We started down this path to help her, and I hope the work we’ve done will give children an easier journey than she had,” Burnett said. “We’re grateful for the support we’ve found here in Dayton and are excited to move forward with this opportunity.”

Dayton Development Coalition (DDC) is the leading economic development organization for the 14- county Dayton region. Working closely with public and private regional partners, its mission is to retain, expand and recruit jobs. The DDC and the Dayton region ranked as the nation’s top metro for its size for economic development in 2008, 2009 and 2012 and runner-up in 2010, 2011, 2014 and 2015. With the State’s largest single-site employer in its backyard, the DDC also focuses on advocating for the critical missions at Wright-Patterson Air Force Base and supporting the work of the United States Air Force. The DDC was ranked as America’s top military community, and was presented with the 2015 Community Excellence Award from the Association of Defense Communities. It was designated as one of the ADC’s Great American Defense Communities in 2016 – a testament to the collaborative efforts in support of Wright-Patt, America’s #1 Air Force Base as ranked by the Air Force Times (2014). For any questions regarding the DDC, contact Shannon Joyce Neal at (937) 723-2047. For more information on AMB, contact Dan Sands, 574-527-1525, or dan.sands@outlook.com.

For any questions regarding the DDC, contact Shannon Joyce Neal at (937) 723-2047. For more information on AMB, contact Dan Sands, 574-527-1525, or dan.sands@outlook.com.

First Choice Announces Share Repurchase Plan

MELBOURNE, FL–(Marketwired – Jun 2, 2017) – First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) (“FCHS,” “First Choice” or the “Company”), one of the nation’s only non-physician-owned, publicly traded healthcare services companies focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedics and spine care, today announced that its Board of Directors unanimously approved a program to repurchase up to one million shares of the company’s common stock.

The authorized repurchases will be made from time to time in either the open market, block transactions, or through privately negotiated transactions. The timing, volume and nature of share repurchases will be at the sole discretion of management, dependent on market conditions, applicable securities laws, and other factors, and may be suspended or discontinued at any time.

“The stock repurchase plan demonstrates our confidence in the strength of our business and commitment to delivering shareholder value,” said Chris Romandetti, President and CEO of First Choice. “We believe our valuation is attractive relative to industry peers and given the company has sufficient cash on hand to support our expansion plans, adding the flexibility to repurchase shares was prudent.”

No assurance can be given that any particular amount of common stock will be repurchased. This repurchase program has no expiration date and is subject to the company’s blackout periods. The program may be modified or terminated by the Board of Directors at any time. The Company will report the repurchases in its periodic reports filed with the U.S. Securities and Exchange Commission.

As of March 31, 2017, First Choice reported approximately $3.9 million in cash with an additional $1.4 million available on a credit facility. First Choice intends to use available cash and future cash flows from operations to fund the repurchase program.

About First Choice Healthcare Solutions, Inc.
Headquartered in Melbourne, Florida, First Choice Healthcare Solutions (FCHS) is implementing a defined growth strategy aimed at expanding its network of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services in key expansion markets throughout the Southeastern U.S. Serving Florida’s Space Coast, the Company’s flagship integrated platform currently administers over 100,000 patient visits each year and is comprised of First Choice Medical Group, The B.A.C.K. Center and Crane Creek Surgery Center. For more information, please visit www.myfchs.com, www.myfcmg.com, www.thebackcenter.net and www.cranecreeksurgerycenter.com.

Safe Harbor Statement
Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of First Choice Healthcare Solutions, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward-looking statements can be found in the Company’s periodic reports on Form 10-K and Form 10-Q, and in its Current Reports on Form 8-K, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.

CONTACT INFORMATION

Interspinous Spacer Market Driven by Increasing Prevalence of Spinal Stenosis Due to Aging, Arthritis, Heredity

Albany, NY — (SBWIRE) — 06/05/2017 — Interspinous spacers sometimes also called as Interspinous process decompression systems, are the devices implanted between vertebral spinous processes. These spacers are made up of a very strong but lightweight metal (titanium) which is biocompatible in the human body. These devices are imbedded in body to confine painful motion else enabling normal motion and to treat lumbar spinal stenosis, discogenic low-back pain, facet syndrome, disc herniations, and non-traumatic instability.

Lumbar spinal stenosis is a thinning of the spinal canal in the lower back which causes compression on nerves and it is developed gradually with age. Radiology tests are used to confirm a diagnosis of moderate degenerative lumbar spinal stenosis. People with lumbar spinal stenosis experience pain but may also have weakness in their leg, lower back and buttocks, numbness, tingling.

Obtain Report Details @ http://www.transparencymarketresearch.com/interspinous-spacer-market.html

The Interspinous spacer are implanted between those vertebrae in such a way that it prevents the patient from bending too far backward which causes pain by surgical procedure. The procedure is very small and sometimes patient can go home within a day.

The increasing prevalence of spinal stenosis due to aging, arthritis, heredity and increased demand of surgical procedures that improved lifestyle and comfort will drive the Interspinous spacer market. The adoption of spacers are increasing due to low complication rate as compared to decompression and spinal fusion. The Interspinous spacers are widely used in geriatric population as per Medicare data due to old age patient are not comfortable with surgery due to their health conditions.

The Interspinous spacer market is segmented as device type, end user and geography. The product type segment is further divided in two type’s statics or compressible and dynamic or non-compressible respectively. The examples of static devices include X STOP, ExtenSure and Wallis implants. These are made up of non-compressible material such as bone, metal or synthetics. The devices produce constant amount of distraction between the spinous processes due to their non-compressible nature. Dynamic Interspinous spacer devices have a degree of compressibility.

 

READ THE REST HERE

Arthromeda Inc. Completes Successful Preclinical Studies and Closes Funding for Its ArthroSight Patient-Specific Navigation Platform

LOWELL, Mass., June 1, 2017 /PRNewswire/ — Arthromeda, Inc., a developer of intelligent orthopedic navigation systems, closed its Series D financing to take the ArthroSight-PS Hip Alignment System (ArthroSight-PS) through commercial regulatory approvals and clinical validation.  This was achieved following a series of successful cadaver labs conducted by surgeon Daniel Ward, MD (New England Baptist Hospital, Boston, MA) at the Cincinnati Children’s Hospital and Medical Center translational research lab (Cincinnati, OH).  The cadaveric studies confirmed that the ArthroSight- PS is an intuitive All-in-One system for accurate and precise implant positioning, providing real-time position angles (inclination and anteversion), leg length and femoral offset difference measurements.  Videos from the labs can be found in Arthromeda’s newly released clinician and patient focused website www.arthromeda.com.

Accurate hip implant positioning is an extremely important factor for patients, physicians, regulators and device companies. In recent years, the number of hip surgeries has skyrocketed with increasing numbers of younger adults getting the procedure according to popular press reports.  Over the 10 years of the study, the number of procedures more than doubled, from 138,700 in 2000 to 310,800 in 2010. The number grew by 92 percent, to 80,000, among those aged 75 and older. It jumped by 205 percent in those aged 45 to 54, to 51,900. Due to the aging baby boomer population, the magnitude of the problem is projected to increase dramatically – doubling by 2030.

“Patient-specific solutions in surgery that are individualized to patients at an affordable cost are important. I am delighted to support Arthromeda in its game-changing mission to help patients undergoing hip arthroplasty experience superior outcomes,” commented Edgar D. Jannotta, Jr., Arthromeda Director and lead investor.

Elsa Chi Abruzzo, RAC, FRAPS, chief operating officer of Arthromeda, commented, “I am grateful to our founder and executive chairman, Mr. PJ Anand, for his clear strategic vision and leadership.  I also appreciate the technical insight of our cofounder and Chief Technical Officer, Mehran Aghazadeh, MD.  We are excited to execute on the next phase of development of this elegant solution for real-time, accurate, acetabular cup positioning and leg length and femoral offset adjustments, without the expensive capital investments or increased procedure time associated with robotic and imaged-based systems.”

Foley Hoag LLP, led by Life Sciences Practice chair Jeffrey Quillen and Patrick Connolly, represented Arthromeda in the financing.  Mr. Quillen & Connolly have represented Arthromeda since its founding in 2011.

About Arthromeda, Inc.

Founded in 2011, Arthromeda, Inc. is a private medical device company focused on developing intuitive, real-time, sensor based, intelligent technologies to improve surgical outcomes for patients undergoing joint replacement procedures.  As part of its extensive patent protected intellectual property portfolio, Arthromeda has created two distinct, yet complimentary, technology platforms to reduce operating room time, improve patient outcomes, and reduce the cost burden associated with early implant failure.   More information can be found at www.arthromeda.com

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org

 

SOURCE Arthromeda, Inc.

Related Links

http://www.arthromeda.com/

RTI Surgical® Partners in New Manufacturing USA Institute

June 02, 2017

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical (RTI) (Nasdaq: RTIX), a global surgical implant company, is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the twelfth Manufacturing USA institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.

Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute on behalf of the Department of Defense.

Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading advanced manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue biofabrication technology in order to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.

“We need to develop twenty-first century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a fifteenth century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.

ARMI’s efforts are supported by forty-seven industrial partners, twenty-six academic and academically affiliated partners, and fourteen government and nonprofit partners. The ARMI partnership continues to grow.

“RTI Surgical is pleased to participate in the ARMI consortium,” said Todd Goede, Global Vice President of Research and Development. “We look forward to providing the regenerative manufacturing resources and knowledge that we use every day to help patients – undoubtedly, the lives of many will benefit from the innovations this initiative will create.”

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

About ARMI

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is the 12th Manufacturing USA Institute. It brings together a consortium of nearly 100 partners from across industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI will work to organize the current fragmented domestic capabilities in tissue biofabrication technology to better position the U.S. relative to global competition. For more information on ARMI, please visit www.ARMIUSA.org.

Contacts

RTI Surgical
Roxane Wergin, Phone: 386-418-8888
Director, Corporate Communications
rwergin@rtix.com